Design, physicochemical characterization, and optimization of organic solution advanced spray-dried inhalable dipalmitoylphosphatidylcholine (DPPC) and dipalmitoylphosphatidylethanolamine poly(ethylene glycol) (DPPE-PEG) microparticles and nanoparticles for targeted respiratory nanomedicine delivery as dry powder inhalation aerosols

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 275-293

  Meenach, Samantha A ^a,b   Vogt, Frederick G ^c   Anderson, Kimberly W ^b,d   Zach Hilt, J ^b,d   McGarry, Ronald C ^a   Mansour, Heidi M ^a,d  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c GLAXOSMITHKLINE   (United States)

^d UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Biocompatible biodegradable lipopolymers; Lipospheres; Lung surfactant; Pulmonary delivery; Self assemblies; Solid state

Indexed keywords

DIPALMITOYLPHOSPHATIDYLCHOLINE; DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; MACROGOL;

AEROSOL; ARTICLE; CHEMICAL STRUCTURE; CONCENTRATION (PARAMETERS); CONFOCAL MICROSCOPY; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DRUG DELIVERY SYSTEM; INFRARED SPECTROSCOPY; NANOFABRICATION; PARTICLE SIZE; PHASE TRANSITION; PHOSPHOLIPID BILAYER; PHYSICAL CHEMISTRY; POWDER INHALER; PROCESS DESIGN; PROCESS OPTIMIZATION; SCANNING ELECTRON MICROSCOPY; SPRAY DRYING; X RAY POWDER DIFFRACTION;

EID: 84872944335     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S30724     Document Type: Article

References (55)

1. Carvalho TC, Carbalho SR, McConville JT. Formulations for pulmonary administration of anticancer agents to treat lung malignancies. J Aerosol Med Pulm Drug Deliv. 2011;24:61-80.
2. Mansour HM, Rhee YS, Wu X. Nanomedicine in pulmonary delivery. Int J Nanomedicine. 2009;4:299-319.
3. Vaughn JM, McConville JT, Burgess D, etal. Sing dose and multiple dose studies of itraconazole nanoparticles. Eur J Pharm Biopharm. 2006;63:95-102.
4. Gill S, Löbenberg R, Ku T, Azarmi S, Roa WH, Prenner EJ. Nanoparticles: characteristics, mechanisms of action, and toxicity in pulmonary drug delivery - a review. J Biomed Nanotechnol. 2007;3:107-119.
5. Yang Y, Bajaj N, Xu P, Ohn K, Tsifansky MD, Yeo Y. Development of highly porous large PLGA microparticles for pulmonary drug delivery. Biomaterials. 2009;30:1947-1953.
6. Sharma S, White D, Imondi A, Placke ME, Vail DM, Kris MG. Development of inhalation agents for oncologic use. J Clin Oncol. 2001;19:1839-1847.
7. Hickey AJ, Mansour HM. Delivery of drugs by the pulmonary route. In: Florence AT, Siepmann J, editors. Modern Pharmaceutics. 5th ed. New York: Taylor and Francis; 2009;2:191-219.
8. Hickey AJ, Mansour HM. Formulation challenges of powders for the delivery of small molecular weight molecules as aerosols. In: Rathbone MJ, Hadgraft J, Roberts MS, Lane ME, editors. Modified-Release Drug Delivery Technology. 2nd ed. New York: Informa Healthcare; 2008;2:573-602.
9. Arnold MM, Gonnan EM, Schieber LJ, Munson EJ, Berkland C. NanoCipro encapsulation in monodisperse large porous PLGA microparticles. J Control Release. 2007;121:100-109.
10. Cartiera MS, Ferreira EC, Caputo C, Egan ME, Caplan MJ, Saltzman WM. Partial correction of cystic fibrosis defects with PLGA nanoparticles encapsulating curcumin. Mol Pharm. 2010;7: 86-93.
11. Meenach SA, Kim YJ, Kauffman KJ, Kanthamneni N, Bachelder EM, Ainslie KM. Synthesis, optimization, and characterization of camptothecin-loaded acetalated dextran porous microparticles for pulmonary delivery. Mol Pharm. 2012;9:290-298.
12. Oh YJ, Lee J, Seo JY, etal. Preparation of budesonide-loaded porous PLGA microparticles and their therapeutic efficacy in a murine asthma model. J Control Release. 2011;150:56-62.
13. Wu XA, Li XJ, Mansour HM. Surface analytical techniques in solid-state particle characterization for predicting performance in dry powder inhalers. Kona Powder Part J. 2010;28:3-19.
14. Mansour HM, Rhee YS, Park CW, DeLuca PP. Lipid nanoparticulate drug delivery and nanomedicine. In: Moghis A, editor. Lipids in Nano-technology. Urbana (IL): American Oil Chemists Society (AOCS) Press; 2011:221-268.
15. Watts AB, McConville JT, Williams RO. Advancements in dry powder delivery to the lung. Drug Dev Ind Pharm. 2008;34:948-959.
16. Patton JS, Byron PR. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov. 2007;6:67-74.
17. Sung JC, Pulliam BL, Edwards DA. Nanoparticles for drug delivery to the lungs. Trends Biotechnol. 2007;25:563-570.
18. Laube BL, Janssens HM, de Jongh FHC, etal. What the pulmonary specialist should know about inhalation therapies. Eur Respir J. 2011;37:1308-1331.
19. Xu Z, Mansour HM, Hickey AJ. Particle interations in dry powder inhaler unit processes. J Adhes Sci Technol. 2011;25:451-482.
20. Rhee YS, Mansour HM. Nanopharmaceuticals I: nanocarrier systems in drug delivery. Invited paper. Int J Nanotechnology. 2011;8:84-114.
21. Wu X, Mansour HM. Nanopharmaceuticals II: application of nano-particles and nanocarrier systems in pharmaceutics and nanomedicine. Invited paper. Int J Nanotechnology. 2011;8:115-145.
22. Willis L, Hayes DJ, Mansour HM. Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery. Lung. 2012;190:251-262.
23. Ganguly S, Moolchandani V, Roche JA, et al. Phospholipid-induced in vivo particle migration to enhance pulmonary deposition. J Aerosol Med Pulm Drug Deliv. 2008;23:181-187.
24. Mansour HM, Zografi G. The relationship between water vapor absorption and desorption by phospholipids and bilayer phase transitions. J Pharm Sci. 2007;96:377-396.
25. Mansour H, Wang DS, Chen CS, Zografi G. Comparison of bilayer and monolayer properties of phospholipid systems containing dipalmitoylphosphatidylglycerol and dipalmitoylphosphatidylinositol. Langmuir. 2001;17:6622-6632.
26. Mansour HM, Zografi G. Relationships between equilibrium spreading pressure and phase equilibria of phospholipid bilayers and monolayers at the air-water interface. Langmuir. 2007;23:3809-3819.
27. Mansour HM, Damodaran S, Zografi G. Characterization of the in situ structural and interfacial properties of the cationic hydrophobic heteropolypeptide, KL4, in lung surfactant bilayer and monolayer models at the air-water interface: implications for pulmonary surfactant delivery. Mol Pharm. 2008;5:681-695.
28. Mabrey S, Sturtevant JM. Investigation of phase transitions of lipids and lipid mixtures by high sensitivity differential scanning calorimetry. Proc Natl Acad Sci U S A. 1976;73:3862-3866.
29. Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol. 2003;56:588-599.
30. Labiris NR, Dolovich MB. Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulation in therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol. 2003;56:600-612.
31. Ishihara K, Nomura H, Mihara T, Kurita K, Iwasaki Y, Nakabayashi N. Why do phospholipid polymers reduce protein adsorption? J Biomed Mater Res. 1998;39:323-330.
32. Mansour HM, Sohn M, Al-Ghananeem A, Deluca PP. Materials for pharmaceutical dosage forms: molecular pharmaceutics and controlled release drug delivery aspects. Int J Mol Sci. 2010;11:3298-3322.
33. Lai SK, O'Hanlon DE, Harrold S, etal. Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc Natl Acad Sci U S A. 2007;104:1482-1487.
34. Sadikot RT, Rubinstein I. Long-acting, multi-targeted nanomedicine: addressing unmet medical need in acute lung injury. J Biomed Nanotechnol. 2009;5:614-619.
35. Lim SB, Rubinstein I, Sadikot RT, Artwohl JE, Önyüksel H. A novel peptide nanomedicine against acute lung injury: GLP-1in phospholipid micelles. Pharm Res. 2011;28:662-672.
36. Kikuchi H, Yamauchi H, Hirota S. A spray-drying method for mass production of liposomes. Chem Pharm Bull. 1991;36:1522-1527.
37. Alves GP, Santana MHA. Phospholipid dry powders produced by spray drying processing: structural, thermodynamic and physical properties. Powder Technol. 2004;145:139-148.
38. Cruz L, Fattal E, Tasso L, et al. Formulation and in vivo evaluation of sodium alendronate spray-dried microparticles intended for lung delivery. J Control Release. 2011;152:370-375.
39. Bosquillon C, Lombry C, Preat V, Vanbever R. Influence of formulation excipients and physical characterisitcs of inhalation dry powders on their aerosolization performance. J Control Release. 2001;70:329-339.
40. Bi R, Shao W, Wang Q, Zhang N. Spray-freeze-dried dry powder inhalation of insulin-loaded liposomes for enhanced pulmonary delivery. J Drug Target. 2008;16:639-648.
41. Masters K. Spray Drying Handbook. 5th ed. Harlow, UK: Longman; 1991.
42. Li X, Mansour HM. Physicochemical characterization and water vapor absorption of organic solution advanced spray dried trehalose microparticles and nanoparticles for targeted dry powder pulmonary inhalation delivery. AAPS Pharm Sci Tech.2011;12:1420-1430.
43. Park CW, Rhee YS, Vogt F, etal. Advances in microscopy and complementary imaging techniques to assess the fate of drugs ex-vivo in respiratory drug delivery: an invited paper. Adv Drug Deliv Rev. 2012;64:344-356.
44. Chapter 601. Aerosols, nasal sprays, metered-dose inhalers, and dry powder inhalers monograph. In: USP 29-NF 24: United States Pharmacopoeia and the National Formulary: The Official Compendia of Standards. Vol 29/24. Rockville, MD: United States Pharmacopeial Convention; 2006:2617-2636.
45. Edwards DA, Ben-Jebria A, Langer R. Recent advances in pulmonary drug delivery using large, porous inhaled particles. J Appl Physiol. 1998;85:379-385.
46. Kang E, Robinson J, Park K, Cheng JX. Paclitaxel distribution in poly(ethylene glycol)/poly(lactide-co-glycolic acid) blends and its release visualized by coherent anti-Stokes Raman scattering microscopy. J Control Release. 2007;122:261-268.
47. Jones BG, Dickinson PA, Gumbleton M, Kellaway IW. The inhibition of phagocytosis of respirable microspheres by alveolar and peritoneal macrophages. Int J Pharm. 2002;236:65-79.
48. Wu YP, Zuo F, Zheng ZH, Ding XB, Peng YX. A novel approach to molecular recognition surface of magnetic nanoparticles based on host-guest effect. Nanoscale Res Lett. 2009;4:738-747.
49. Li X, Hayes D, Mansour HM. Targeted lung delivery by inhalable multifunctional microparticulate/nanoparticulate aerosols for cystic fibrosis combination drug/mucolytic treatment. Pediatric Pulmonology. 2011:34 Suppl:346.
50. Azarmi S, Roa WH, Lobenberg R. Targeted delivery of nanoparticles for the treatment of lung diseases. Adv Drug Deliv Rev. 2008;60: 863-875.
51. Gautam A. Targeted delivery of therapeutics by aerosol for cancer of the lung. Curr Cancer Drug Targets. 2003;3:57.
52. Edwards DA. The macrotransport of aerosol particles in the lung: aerosol deposition phenomena. J Aerosol Sci. 1995;26:293-317.
53. Hickey AJ, Mansour HM, Telko MT, et al. Physical characterization of component particles included in dry powder inhalers. I. Strategy review and static characteristics. J Pharm Sci. 2007;96:1282-1301.
54. Vanbever R, Ben-Jebria A, Mintzes J, Langer C, Edwards DA. Sustained release of insulin from insoluble inhaled particles. Drug Dev Res. 1999;48:178-185.
55. Ungaro F, De Rosa G, Miro A, Quaglia F, La Rotonda MI. Cyclodextrins in the production of large porous particles: development of dry powders for the sustained release of insulin to the lungs. Eur J Pharm Sci. 2006;28:423-432.